TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Body composition assessment using Dual-energy X-ray absorptiometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body composition assessment using bioelectrical impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle strength assessment using the 1-repetition maximum method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein oxidation assessment using stable isotope tracer method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrieved oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change of Malondialdehyde levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Caspase-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with low cardiac output syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who have a positive RNA HCV test
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who have a positive HIV rapid test
Endpoint domain: Adverse events/effects
Primary endpoint: days of headache per month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Pulmonary Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in Cloth tape measurement technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density of lumber spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density of femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma glucose levels over a 2-hour oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma insulin levels over a 2-hour oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in systemic markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nicotine Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of 24-hydroxycholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success in inducing immune tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Total Scores of IRLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Global Clinical Impression - Improvement (CGI-I) Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breast uptake of I-131
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Sequencing of the Fabry disease related gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Residual Effects of Heavy Drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oseltamivir Carboxylate Transmembrane Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Oseltamivir Carboxylate Removal by ECMO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of grade 2-4 acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Parosteal osteosarcoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: pharmacokinetics of atazanavir/ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with CDA ratings R (excellent) or S (acceptable)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: whole-body net protein balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing a Grade 3-5 Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing dose-limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants experiencing grade 1-4 laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Functional Assessment of Cancer Therapy-Lung Total Outcome Index Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lower facial height measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the PET-MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Raynaud's Phenomenon Attacks Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Raynaud's Phenomenon Attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raynaud Severity Visual Analog Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Raynaud's Condition Score (RCS) Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation rate due to gastrointestinal adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of optimal location of the cuffless Oral RAE tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Activities Scale for Kids performance version (ASKp)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Discontinuing Study Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Success of internal jugular vein catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: % of diagnostic quality clips acquired
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neuropsychological measures of attention (test scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Increase in Hemoglobin Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive Percent Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hematopoiesis rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of Subjects Achieving a 40% Decrease in Overall PDSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Worst Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-years overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Cause of death assignment
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Who Experienced a Treatment-related Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Discontinued Study Treatment Due to a Treatment-related Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: HIV testing in the previous month
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Occurrence of symptomatic or incidental VTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pain Relief Sufficient for Discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Net Average Combined Daily Rhinoconjunctivitis Symptom and Medication Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of advanced liver disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Incidence of Freedom From Documented Symptomatic Atrial Fibrillation
Endpoint domain: Adverse events/effects
Primary endpoint: Resource utilisation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient reported function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sleep Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Escudier score of oral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Bone Mass Density (BMD) in the Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change of Bone Mass Density (BMD) in the Femoral Neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pupillometry Assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of structural lung sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of functional lung impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Association between chest CT findings and PFT impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: bacteria translocation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Hospital Anxiety & Depression Scale - Depression (HADS-D) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hospital Anxiety & Depression Scale - Anxiety (HADS-A) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: D90 Quantitative Efficacy Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Potential cardiovascular interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall response rate defined by platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volume of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Annual average total health care cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease Progression-Free-Survival (DPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Psychomotor vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD response to noxious stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects measured by the UKU scale
Endpoint domain: Adverse events/effects
Primary endpoint: Time to integrated histological-molecular diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in performance on the cognitive domain of executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in performance on the cognitive domain of memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in performance on the cognitive domain of attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Preoperative Pain Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative Neuropathic Pain Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival following hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Response rate (complete response [CR] and partial response [PR])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Early Treatment Diabetic Retinopathy Study (ETDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lasbarhetsindex (LIX, Readability Index)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Frequency of ACO exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in daily itch scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of Participants
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of Iphone App
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in IL-8 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Neutrophil Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of cavities filled with problems in marginal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of cavities filled with problems in marginal discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Flow Mediated Vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Negative Symptoms of Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scar quality and appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ventilator-induced lung injury (VILI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of Tethered OFDI Capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Structural empowerment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to Induction Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Modified Ashworth scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from spinal excitability via Hoffmann reflex of the median nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Serum Cross Linking C-telopeptide of Type 1 Collagen (s-CTX-1) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in the Ratio of Carboxylated (c-OC) to Under-carboxylated Osteocalcin (Uc-OC) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of post-randomization adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Adverse Events Related to the Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in self-care behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of hypoxemic acute respiratory failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expanded Disability Status Scale (EDSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of urinary tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: number of pyelonephritis
Endpoint domain: Adverse events/effects
Primary endpoint: daily pain levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Surgical Feasibility Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Response Rate (Complete Response/Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reducing oral analgesic use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average number of days of hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: % of primary care providers completing buprenorphine waiver training
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: FEV1 AUC0-24 standardized by time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) Post Each Dose of Study Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Adverse Events (SAE), Medically Attended Adverse Events (MAAE), and Adverse Event of Special Interest (AESI) Prior to Non-study COVID-19 Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percent rate of patients achieving target LDL cholesterol goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent rate of patients achieving 50% or more reduction in LDL-cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pregnancy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: improvement rate of visual field result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Subjects With a 50% or Greater Improvement in Mean Worst Daily Leg Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of triple combination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Image Quality of Cone Beam Breast CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Neonatal Event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients attaining ASAS20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV related illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of radiographic Parastomal Hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Uptake of 89Zr-DFO-CZP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of study participants who tolerate oral doses of TRx0237 as determined by safety parameter changes
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration of cell-free fetal DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rate of hair thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cancer susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of Fibrosis Based on Liver Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of Aramchol Compared to Placebo on Liver Histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Long-term Outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mechanical complications related to imaging and endoplant
Endpoint domain: Adverse events/effects
Primary endpoint: hypotensive episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Anhedonic Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Brain Activation During a Monetary Reward Gambling Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Performance on the Probabilistic Reward Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Endoscopic grading of atrophic gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endoscopic grading of intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Operative links on gastritis assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Operative links on gastric intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Reduction in SPID Scores of DOMS on Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nutritional efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bronchopulmonary Dysplasia (BPD) or Mortality
Endpoint domain: Mortality/survival
Primary endpoint: self-reported general self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-reported social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: self-reported strengths and difficulties
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing